Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q3 2022 · 10-Q
Revenue$414.25K$414.25K+18.6% vs Q3 2021 Net Income-$804.02K-$804.02KN/M vs Q3 2021 EPS Diluted-$0.56-$0.56N/M vs Q3 2021 Operating Income-$847,786N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-204.7%+189.3 pt vs Q3 2021
Net margin-194.1%+192.7 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 9, 2022 · 40 d after period end